Selpercatinib Disease Interactions
There are 5 disease interactions with selpercatinib:
Selpercatinib (Includes selpercatinib) ↔ bleeding
Moderate Potential Hazard, Moderate plausibility. Applies to: Bleeding
Serious including fatal hemorrhagic events can occur with the use of selpercatinib. Care should be exercised when using this agent in patients with bleeding disorders. It is recommended to permanently discontinue treatment in patients with severe or life-threatening hemorrhage.
Selpercatinib (Includes selpercatinib) ↔ hypertension
Moderate Potential Hazard, Moderate plausibility. Applies to: Hypertension
Selpercatinib may cause hypertension and therapy should not be initiated in patients with uncontrolled hypertension. Care should be exercised when using this agent in hypertensive patients. Optimize blood pressure before starting treatment. It is recommended to monitor blood pressure after 1 week, and regularly as clinically indicated. Initiate or adjust anti-hypertensive therapy as appropriate. Withhold, reduce dose, or permanently discontinue treatment based on the severity.
Selpercatinib (Includes selpercatinib) ↔ liver dysfunction
Moderate Potential Hazard, Moderate plausibility. Applies to: Liver Disease
Selpercatinib is metabolized predominantly by CYP450 3A4. The dose of selpercatinib should be reduced in patients with severe hepatic impairment. No dosage modification is recommended for patients with mild or moderate hepatic impairment. Serious hepatic adverse reactions have been reported in patients treated with selpercatinib. Monitor ALT and AST before starting therapy with selpercatinib, every two weeks during the first three months, then monthly thereafter and as clinically indicated. It is recommended to withhold, reduce dose or permanently discontinue treatment based on the severity of selpercatinib-related adverse reactions in patients with hepatic impairment.
Selpercatinib – arrhythmias
Moderate Potential Hazard, Moderate plausibility. Applies to: Arrhythmias, Hypokalemia, Magnesium Imbalance, Hypocalcemia, Electrolyte Abnormalities, Thyroid Disease
Selpercatinib can cause concentration-dependent QT interval prolongation. It is recommended to assess QT interval, electrolytes, and TSH at baseline and periodically during treatment and to adjust treatment based upon risk factors. Correct hypokalemia, hypomagnesemia, and hypocalcemia before initiating treatment. Monitor regularly for these laboratory values and correct them as clinically appropriate. Withhold, reduce the dose or permanently discontinue treatment based on the severity.
Selpercatinib – renal dysfunction
Moderate Potential Hazard, Moderate plausibility. Applies to: Renal Dysfunction
The use of selpercatinib may increase serum creatinine. It is recommended to consider alternative markers of renal function if persistent elevations in serum creatinine are observed. No dosage modification is recommended for patients with mild to moderate renal impairment. Exercise caution when using this agent in patients with severe renal impairment or end-stage renal disease as the recommended dosage has not been established for these patients.
Selpercatinib drug interactions
There are 535 drug interactions with selpercatinib
Selpercatinib alcohol/food interactions
There are 2 alcohol/food interactions with selpercatinib
More about selpercatinib
- Side Effects
- During Pregnancy
- Dosage Information
- Drug Interactions
- En Español
- Drug class: multikinase inhibitors
Related treatment guides
Drug Interaction Classification
|Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.|
|Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.|
|Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.|
|No interaction information available.|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.